Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.59 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897601 | 0.86 | RXRA (0.51) | RXRA | |
| SCHEMBL5761006 | 0.78 | RXRA (0.73) | RXRA | |
| SCHEMBL5761002 | 0.78 | RXRA (0.73) | RXRA | |
| SCHEMBL5786173 | 0.77 | RXRA (0.71) | RXRAGSK3B | |
| SCHEMBL5786174 | 0.77 | RXRA (0.71) | RXRAGSK3B | |
| SCHEMBL5792298 | 0.76 | RXRA (0.70) | RXRA | |
| SCHEMBL5758043 | 0.76 | RXRA (0.70) | RXRA | |
| SCHEMBL5650577 | 0.74 | RXRA (1.00) | RXRA | |
| SCHEMBL2659640 | 0.74 | RXRA (1.00) | RXRA | |
| SCHEMBL5650580 | 0.74 | RXRA (1.00) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | claimed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | RXRA 955/4885GLS 1245/4885GLS2 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.